Federal Trade Commission v. Watson Pharmaceuticals, Inc.
677 F.3d 1298
11th Cir.2012Background
- FTC alleges reverse payment settlements among Solvay, Watson, Par, and Paddock concerning AndroGel patent litigation; settlements delayed generic entry to 2015 and included promotional payments.
- AndroGel received FDA approval in 2000; Solvay obtained the '894 patent (expires 2020) and listed it in the Orange Book; 180-day exclusivity incentives encouraged challenges to weak patents.
- Watson and Paddock filed ANDAs with paragraph IV certifications; FDA stayed approval for 30 months pending infringement litigation.
- Settlement agreements mapped out a shared strategy: no generic entry until 2015 absent earlier launch; Solvay paid Par/Paddock and shared profits with Watson; the group dismissed the infringement case in district court.
- FTC filed suit in district court alleging unlawful restraints on competition under FTC Act and Sherman Act; district court dismissed, ruling FTC failed to allege exclusion beyond the patent’s scope.
- The Eleventh Circuit affirms, applying Valley Drug/Schering-Plough/Andrx framework that reverse payments are immune if effects stay within the patent’s exclusionary potential; FTC’s “not likely to prevail” claim does not state a claim at Rule 12(b)(6) stage.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether reverse payments are per se illegal or immune if within patent scope | FTC argues exclusionary effects exceed patent scope; payments buy off competition. | Solvay et al. argue patent rights justify settlements; not beyond scope. | Not per se unlawful; analysis within patent’s exclusionary potential suffices. |
| Whether alleging Solvay was not likely to prevail states an antitrust claim | FTC contends not likely to prevail negates patent exclusion; antitrust violation. | Defendants assert likelihood is not same as certainty; remains within patent scope. | Court rejects, requiring effect within patent scope, not likelihood language. |
| What standard governs review of Rule 12(b)(6) in patent-antitrust settlements | Court applies de novo review using plausibility framework; rejects FTC retrofit approach. | ||
| Whether prior Valley Drug/Schering-Plough/Andrx framework controls this case | Yes; reverse payments immune if within patent's exclusionary potential; not here if beyond scope. |
Key Cases Cited
- Valley Drug Co. v. Geneva Pharmaceuticals, Inc., 344 F.3d 1294 (11th Cir. 2003) (established three-prong test; patent scope matters for antitrust immunity)
- Schering-Plough Corp. v. FTC, 402 F.3d 1056 (11th Cir. 2005) (rejected per se rule; require assessment of patent exclusionary scope vs. settlement terms)
- Andrx Pharmaceuticals, Inc. v. Elan Corp., 421 F.3d 1227 (11th Cir. 2005) (held plausible antitrust claim where settlement blocked competition beyond patent scope or corked exclusivity)
- Valley Drug Co. v. Geneva Pharmaceuticals (cited within opinion), 344 F.3d 1294 (11th Cir. 2003) (phased approach to patent exclusion and settlement effects; not immune if beyond exclusionary scope)